Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385877 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines
A Early Phase 1 study of Autonomic Peripheral Nervous System Diseases, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02385877: Completed Early Phase 1 study of Autonomic Peripheral Nervous System Diseases, sponsored by University of Michigan.
NCT02385877 is a Early Phase 1 study of Autonomic Peripheral Nervous System Diseases that has completed, run by University of Michigan. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02385877, a Early Phase 1 study of Autonomic Peripheral Nervous System Diseases, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).
Primary Outcome
These data will be used to select the lead radiotracer for further clinical development.
Conditions Studied
Interventions
- DRUG [18F]4F-MHPG
- DRUG [18F]3F-PHPG
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | Early Phase 1 |
What the finished NCT02385877 record still lists
NCT02385877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Autonomic Peripheral Nervous System Diseases appearing as the primary indexed condition, and to 2 interventions - of which [18F]4F-MHPG is the first listed.
NCT02385877 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02385877 about?
NCT02385877 is a clinical study titled "Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines". The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).
What is the current status of trial NCT02385877?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2015-03. Estimated completion is 2016-08.
What conditions does trial NCT02385877 study?
This clinical trial studies the following conditions: Autonomic Peripheral Nervous System Diseases.
What interventions are being tested in trial NCT02385877?
The interventions under investigation include: [18F]4F-MHPG (DRUG), [18F]3F-PHPG (DRUG).
Who is sponsoring clinical trial NCT02385877?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02385877 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02385877's enrollment target sits among peer trials
16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia